Skip to main content
OpenTrials
Completed

NCT Number: NCT02009696

ProMRI Study of the Entovis Pacemaker System (Phase B)

The objective of the ProMRI Study (Phase B) is to demonstrate the clinical safety of the ProMRI Pacemaker System when used under specific MRI conditions without scan exclusion zone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Phoenix, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The following initial inclusion criteria must be met for a subject to be enrolled and considered for the MRI-procedure:

  • Age greater than 18 years
  • Able and willing to complete MRI testing
  • Able to provide written informed consent
  • Available for follow-up visit at the study site
  • Implanted with a pacemaker system consisting only of an Entovis pacemaker (DR-T, SR-T) and one or two Setrox S 53 or Setrox S 60 pacemaker lead(s). (No leads other than Setrox S (53 or 60 cm) leads may be implanted. This includes lead extensions or abandoned leads in the subject.)
  • Pacemaker implanted pectorally
  • All pacemaker system components implanted, repositioned, or exchanged at least 5 weeks prior to enrollment
  • Underling rhythm identifiable during sensing test
  • All pacing thresholds are measureable and are less than or equal to 2.0 V @0.4 ms
  • Absence of phrenic nerve stimulation at 4.8V @ 1.0 ms
  • Pacing impedance is between 200 and 1500 ohm
  • Able and willing to use the Cardio Messenger

At the pre-MRI procedure, the following procedure-related criteria must be met for the subject to undergo the MRI scan:

  • Absence of phrenic nerve stimulation at 4.8V @ 1.0 ms

•|pacing threshold at Pre-MRI follow-up - pacing threshold at baseline| ≤ 0.5 V

  • All pacing thresholds are measureable and are ≤ 2.0 V @ 0.4 ms
  • The pacemaker system has been implanted for at least 6 weeks.
  • Subject did not have a pacemaker or lead explant, exchange or reposition in the previous 6 weeks.
  • All lead impedances are between 200 and 1500 ohm.
  • Battery status is at least 30% of capacity

Exclusion criteria

  • Enrolled in any other clinical study
  • For pacemaker systems that include an atrial lead, subjects with either
  • Persistent atrial arrhythmia (lasting longer than 7 days or requiring cardioversion)
  • Permanent atrial arrhythmia
  • Life expectancy of less than three months
  • Pregnancy
  • Cardiac surgery expected in the next three months

Implanted with other medical devices that may interact with MRI, such as:

  • abandoned pacemaker/ICD leads
  • lead extensions
  • mechanical valves
  • other active medical devices
  • non-MRI compatible devices
  • other metallic artifacts/components in body that may interact with MRI

Treatment and study plan

Patients with a ProMRI Pacemaker System

Device

Bradycardia Slow Heart Beat

Magnetic Resonance Imaging (MRI) Scan

Other

MRI scan of heart/chest or thoracic spine.

Primary outcomes

  1. MRI and Pacing System Related Serious Adverse Device Effect (SADE) Free Rate

    Time frame: 1 Month Post-MRI

  2. Percentage of Participants Free of Atrial Pacing Threshold Rise

    Time frame: Between Pre-MRI and 1 Month Post-MRI

    Evaluate the percentage of atrial pacing leads with a pacing threshold increaess between the Pre-MRI and one-month post-MRI follow-up.

  3. Percentage of Participants Free of Ventricular Pacing Threshold Rise

    Time frame: Between Pre-MRI and 1 Month Post-MRI

    Evaluate the percentage of ventricular pacing leads with a pacing threshold increase between the Pre-MRI and one-month post-MRI follow-up.

  4. Percentage of Participants Free of P-wave Sensing Attenuation

    Time frame: Between Pre-MRI and 1 Month Post-MRI

    Evaluate the percentage of subjects who experience P-wave attenuation between the pre-MRI and one-month post-MRI follow-up.

  5. Percentage of Participants Free of R-wave Sensing Attenuation

    Time frame: Between Pre-MRI and 1 Month Post-MRI

    Evaluate the percentage of subjects who experience R-wave attenuation between the pre-MRI and one-month post-MRI follow-up.

Sponsors and collaborators

Lead sponsor

Biotronik, Inc.

Industry

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2015
First posted
Dec 12, 2013
Registry last updated
Nov 25, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.